|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Nanogen, Inc., a developer of advanced technologies to predict, diagnose, and treat disease (PCR agents, electronic microarray platforms, rapid diagnostic kits, etc.) |
|---|---|
| Transferring Party | The rapid cardiac immunoassay test business of Spectral Diagnostics, Inc., developer of innovative technologies for comprehensive disease management. |
| Sector | Diagnostics |
| Date | February 7, 2006 |
| Analysis Accelerates Nanogen's growth strategy to become a leading advanced diagnostics company; complements Nanogen's Congestive Heart failure test. Total consideration for the Deal is CDN$9m, comprised of CDN$5.65m in cash and CDN$3.35m in Nanogen shares. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |